Modern vaccine side effects: male myocarditis 12-29 years, hypothesis

“A small increase in cases of myocarditis was seen” among the side effects after the administration of Moderna’s anti-Covid vaccine, compared to that of Pfizer / BioNTech, “in males aged 12 to 29”. This observation “concerns the primary vaccination course and not the booster dose”. The increase in myocarditis “was not observed in females”, suggesting that “testosterone may be a contributing factor” to this “rare side effect”. In any case, the detected myocarditis is “typically mild and self-healing”. This was clarified by Paul Burton, Moderna’s Chief Medical Officer, during a press briefing convened by the American company after the use of Spikevax was limited to the age groups over 30 years old in some countries, most recently Germany. . “Moderna’s Covid vaccine has been used in more than 155 million people worldwide, demonstrating exceptional efficacy and duration of protective effect, in different populations and against different variants” of the SARS-Cov-2 coronavirus, he said. underlined the expert, illustrating data from the real world collected from several countries, which would indicate an efficacy even higher for the Moderna vaccine than that obtained with the Pfizer / BioNTech vaccine. “Government reports in the US and Switzerland, countries with high immunization rates with Moderna – stressed Burton – show that the vaccine is highly effective in reducing the risk of Covid infections, of ‘breakthrough’ infections”, that is post-vaccination infections , “of hospitalizations and deaths. Real-world studies in millions of individuals indicate a similar result.” Myocarditis, the US company’s CMO continued, “has been identified as a rare side effect of mRna and Spikevax vaccine (mRna-1273) some health authorities have noted that it has a slightly higher risk of myocarditis “in 12-29 year olds,” compared to Bnt162b2, ie Pfizer / BioNTech’s Comirnaty. This excess of myocarditis was observed in 12-29 year old males with a difference between the two products equal to “about 10 cases per 100 thousand vaccinated”: the data shown by Burton comes from France and in the report in question 13.3 cases are reported of myocarditis in excess of 100 thousand immunized with Moderna, against 2.7 cases / 100 thousand for Comirnaty. Over the age of 30, the myocarditis data collapses with both mRna vaccines (in the 30-50 year olds the myocarditis excess is limited to 2.7 cases per 100 thousand immunized with Moderna and 0.5 cases / 100 thousand with Pfizer). “Data the effectiveness of the vaccine “which, according to the Norwegian Institute of Public Health” seems to provide somehow greater protection than Comirnaty against mild and severe forms of Covid caused by the Delta variant “, Moderna” believes – concluded Burton – that the relationship between benefits and risks is very positive “.